SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Patel Samir Rashmikant (Last) (First) (Middle) C/O AKARI THERAPEUTICS PLC 401 EAST JACKSON STREET, SUITE 3300 (Street) TAMPA FL 33602 (City) (State) (Zip)	Akari Therapeutics Plc [AKTX] 3. Date of Earliest Transaction (Month/Day/Year) 07/07/2026 4. If Amendment, Date of Original Filed (Month/Day/Year)	☑ Director ☑ 10% Owner ☐ Officer (give title below) ☐ Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) ☑ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
American Depositary Shares representing Ordinary Shares	07/07/2026		M		1,209	A	$8	76,976	I	PranaBio Investments LLC
American Depositary Shares representing Ordinary Shares	07/07/2026		M		15,466	A	$0.0004	92,442	I	PranaBio Investments LLC
American Depositary Shares representing Ordinary Shares	07/07/2026		M		5,799	A	$0.0004	98,241	I	PranaBio Investments LLC
American Depositary Shares representing Ordinary Shares								3,566	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Pre-Funded Warrant to purchase American Depositary Shares[(1)]	$8	07/07/2026		M		1,209		10/06/2023	[(2)]	American Depositary Shares representing Ordinary Shares	1,209	$32	0	I	PranaBio Investments LLC
Pre-Funded Warrant to purchase ADSs	$0.0004	07/07/2026		M		15,466		[(3)]	[(2)]	American Depositary Shares representing Ordinary Shares	15,466	$16.16[(4)]	0	I	PranaBio Investments LLC
Pre-Funded Warrant to purchase ADSs[(5)]	$0.0004	07/07/2026		M		5,799		[(3)]	[(2)]	American Depositary Shares representing Ordinary Shares	5,799	$16.16[(5)]	0	I	PranaBio Investments LLC

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share.
2. The pre-funded warrants remain exercisable until fully exercised.
3. The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
4. The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16.
5. On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued

interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs.

/s/ Abizer Gaslightwala, as Attorney-in-Fact	07/17/2026
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.